CD30 Is Highly Expressed in Chronic Obstructive Pulmonary Disease and Induces the Pulmonary Vascular Remodeling

Abstract EN

Chronic obstructive pulmonary disease (COPD) is one of the common and underdiagnosed diseases with the highest morbidity and mortality in the world.

The development of COPD can lead to pulmonary vascular remodeling and pulmonary hypertension, further causing the occurrence of pulmonary heart disease.

Therefore, attenuation of pulmonary vascular remodeling and pulmonary hypertension caused by COPD can significantly delay cardiovascular complications.

In the study, we firstly found that the expression of CD30 and CD30L was increased in COPD.

Importantly, the serum CD30L levels were significantly higher in patients with stable COPD relative to those with acute exacerbation of COPD (AECOPD).

This suggested that CD30 might be related to the development of COPD.

In addition, we found that the expression of CD30 in the COPD rat model was significantly increased compared with control group.

And treatment with the anti-CD30 antibody reduced the serum concentration and tissue expression of CD30 in rat.

Importantly, anti-CD30 antibody alleviated pulmonary vascular remodeling in COPD model rats.

This suggested that CD30 played an important role in the course of COPD.

Finally, we found that, in the HPASMC and HPAEC cell lines, CD30 can affect the cell viability and cell migration and inhibited hypoxia-induced cell apoptosis in a concentration-dependent manner.

We also found CD30 induced extracellular matrix formation through decreasing the expression of MMP-2, thus promoting the pulmonary vascular remodeling.

The study indicated that CD30 and CD30L were involved in pulmonary vascular remodeling and inflammatory response in COPD.

Altogether, CD30 might be a marker for the early diagnosis and progression of COPD.